action of glp-1 agonist Frontiers Clinical Focus on GLP-1 Agonists

These treatments have fundamentally changed how we address chronic weight management by working with the bodys natural biology to manage appetite

This pathway has been beautifully illustrated by Krajnc et al

DPP4is (e.g., sitagliptin, saxagliptin, vildagliptin, linagliptin, alogliptin, and teneligliptin) are a group of oral medications designed to manage T2DM by prolonging the activity of incretin hormones (GLP1 and GIP)

M., Diabetes Type 2 Management: What Are the Differences Between DPP4 Inhibitors and How Do You Choose?, Expert Opinion on Pharmacotherapy 18, no

In a NewsNation article from November 2025, addiction specialist Dr

They're being marketed as nootropics for cognitive enhancement